In 2021, the veterinary drug API industry continues to usher in new living water, expansion, new construction, China Veterinary Drug Feed Trading Center on 2021 veterinary drug API industry related investment and new production on the line incomplete statistics, for everyone to view and know, if there is any omission, welcome to leave a message below to supplement.
1. Inner Mongolia Huashu Phase II project with an annual output of 10,000 tons of oxytetracycline alkali started construction
The biopharmaceutical project of Inner Mongolia Huashu Biotechnology Co., Ltd. is located in Kailu County, which is built in three phases with a total investment of 3 billion yuan. At present, the first phase of the project has reached full production and effectiveness, driving the employment of 500 people. The second phase of the oxytetracycline alkali project with an annual output of 10,000 tons has completed the grooving project of part of the plant foundation. After the full project is put into operation, Kailu County will become the world's largest oxytetracycline production base.
2. Hunan Luheng Shiyuan Animal Pharmaceutical Industrial Park project settled in Shaoshan
On January 13, Hunan Luheng Shiyuan Animal Pharmaceutical Industrial Park project was officially signed. It is understood that Hunan Luheng Shiyuan Animal Pharmaceutical Industrial Park is invested and constructed by Hunan Lvheng Shiyuan Animal Pharmaceutical Co., Ltd., a holding subsidiary of Beijing Luheng Technology Group, with an investment of 108 million yuan, will build a standardized plant of about 20,000 square meters, introduce 20 veterinary drug standard production lines, mainly engaged in animal health powder injections, powders, oral solutions, compound premixed feed and other products research and development, production and sales.
3. Jinhe Biotech: It is proposed to set up a holding subsidiary with related parties to implement the doxycycline hydrochloride project
Jinhe Bio announced that the company intends to invest 50 million yuan with Jin Yiyuan, Jinhe Holdings, natural person Liu Yunlong and others to establish a subsidiary Inner Mongolia Jinhe Pharmaceutical Technology Co., Ltd. (tentative name, the final industrial and commercial registration shall prevail), and the holding subsidiary is responsible for the implementation of the "doxycycline hydrochloride project". The newly established company Jinhe Pharmaceutical Company has a registered capital of 50 million yuan, and the company invests 25.5 million yuan in cash with its own funds to hold 51% of the equity.
In June 2021, Inner Mongolia Jinhe Pharmaceutical Technology Co., Ltd. participated in the second public announcement of the environmental impact assessment of the 1,000 tons of doxycycline hydrochloride project.
4. Jinhe Biology 660 million tons of veterinary drug grade API project
On September 6, the groundbreaking ceremony of Jinhe Biology's annual output of 52,000 tons of veterinary drug grade high-efficiency chlortetracycline 1,000 tons of chlortetracycline hydrochloride API project was held. It is understood that the total investment of the project is 660 million yuan, and it is planned to be completed and put into operation in May 2023.
5. Zhengze Biological Green Agricultural veterinary drugs, medicine and intermediates project is scheduled to start construction in April
It was learned from the Kailu Party Building that the Zhengze Biological Green Agricultural veterinary drug, medicine and intermediates project with a total investment of 2 billion yuan and covering an area of 1,000 mu has completed more than 80% of the preliminary work such as environmental impact assessment, safety assessment and design, and has the conditions for starting construction, and is scheduled to start construction in April.
6. Huisheng Bio will invest in the expansion project of Tylosin production line with an annual output of 1,000 tons and tylomercin with an annual output of 600 tons
Huisheng Biotech disclosed a plan to issue convertible corporate bonds to unspecified targets. The total amount of funds raised in the offering will not exceed RMB720 million, and after deducting the issuance fee, it will invest in the expansion project of the 1,000 tons of Tyloxin and 600 tons of Tylosin production line per year, the automation comprehensive transformation and expansion project of The Hubei Huisheng Preparation Production Line, the construction project of the pet preparation comprehensive production line, the expansion project of the powder/premix production line and the supplementary working capital.
7. The 2,000-ton doxycycline project with a total investment of 1.3 billion yuan is being leveled
The reporter learned from the website of the Inner Mongolia Development and Reform Commission that the 2,000-ton doxycycline project of Zhonghui Pharmaceutical with a total investment of 1.3 billion yuan, the veterinary drug base project of Hebei Jiupeng Pharmaceutical with a total investment of 3.5 billion yuan, the Zhengze Biological Green Agricultural Veterinary Drug and Pharmaceutical Intermediates Project with a total investment of 2 billion yuan, and the huaxin Pharmaceutical high-end API and intermediate project with a total investment of 1 billion yuan are being leveled in Kailu.
8. With a total investment of about 8 billion yuan, "China Veterinary Medicine Valley" settled in Zaozhuang Economic Development Zone
"China Veterinary Medicine Valley" settled in Zaozhuang Economic Development Zone, Shandong Province. It is understood that the total investment of the project is about 8 billion yuan, the planning covers an area of 3305 acres, focusing on veterinary biological products, veterinary chemical preparations, veterinary proprietary Chinese medicine preparations and corresponding excipients, equipment and other fields, mainly planning and construction of biological products industry sector, chemical pharmaceutical industry sector, Chinese veterinary medicine industry sector, supporting service industry sector and other 4 major areas.
9. The second phase of the pharmaceutical intermediate project of Inner Mongolia Qihui Pharmaceutical has entered the trial production stage
The second phase of the pharmaceutical intermediate project of Inner Mongolia Qihui Pharmaceutical has been installed and debugged, and trial production has begun. It is understood that in 2019, Inner Mongolia Qihui Pharmaceutical co., Ltd. invested a total of 1 billion yuan to build the pharmaceutical intermediate project of Inner Mongolia Qihui Pharmaceutical Co., Ltd., and built five kinds of veterinary APIs in two phases, including albendazole, fenbendazole, mebendazole, dikezuli, and pentachlorosalium, and after the project was fully completed and put into operation, the annual output of albendazole was 1500 tons, fenbendazole was 300 tons, mebendazole was 200 tons, dikruly 50 tons, and pentachloral salium was 500 tons. The first phase of the project, with an investment of 400 million yuan, was officially completed and put into operation last year.
10. Jiangsu Huan Pharmaceutical Co., Ltd. invested 2 billion yuan to build an annual output of 5,000 tons of oxytetracycline hydrochloride and doxycycline hydrochloride project in Kailu County
Tongliao City, Kailu County, Jiangsu Lianhuan Pharmaceutical Group signed an agreement on the api and finished drug base project. It is understood that the total investment of the API and finished drug base project signed this time is 4 billion yuan, and the first phase of investment is 2 billion yuan to build an annual output of 5,000 tons of oxytetracycline hydrochloride and doxycycline hydrochloride and other API production lines; the second phase of investment is 2 billion yuan to build a finished drug production line such as epliprit tablets, tefenadine tablets, ebastine tablets, felodipine tablets, felodipine sustained release capsules and so on.
11. Xianfeng Holdings: 1.2 times premium to acquire and transform to sell "veterinary drugs"
Xianfeng Holdings announced that the company intends to purchase 70% of the equity of Chengdu Tianbang and 70% of the equity of Shiji Biology, with transaction prices of 322 million yuan and 35 million yuan respectively. Among them, the appreciation rate of Chengdu Tianbang is 121.34%. It is reported that Chengdu Tianbang is a national high-tech enterprise integrating research and development, production, sales and technical services of veterinary biological products.
12. Raise 563 million yuan to invest in the construction of three major projects! Shengtaier intends to build a leading domestic veterinary drug company
On June 29, Beijing Shengtaier Technology Co., Ltd.'s GEM IPO application was accepted by the Shenzhen Stock Exchange. The company intends to publicly issue no more than 19.16 million ordinary shares to the public, and plans to use the raised funds of 563 million yuan to invest in the first phase of the construction of the GMP base for veterinary biological products, the construction project of the R&D center, and the supplementary working capital. According to the prospectus, Shengtaier is committed to the research and development, production and sales of veterinary drugs and related products, and the main products include veterinary traditional Chinese medicine, veterinary vaccines, pre-mixed feeds, veterinary chemical drugs, etc.
13. Federal Pharmaceutical intends to establish a joint venture with Zhejiang Puluo to carry out strategic cooperation in the field of veterinary drugs
Federal Pharmaceutical announced that federal pharmaceutical (Inner Mongolia) Co., Ltd., a wholly-owned subsidiary of the company, and Zhejiang Puluo Biotechnology Co., Ltd. jointly signed a framework agreement on cooperation in veterinary drugs. According to the cooperation framework agreement, Federal Pharmaceutical (Inner Mongolia) and Zhejiang Puluo will establish an operating joint venture company in cash with a registered capital of RMB 300 million, and Federal Pharmaceutical (Inner Mongolia) will hold 49% of the equity of the joint venture company.
14. Zhongmu shares: It is planned to increase the capital of Zhongmu Nanjing Animal Pharmaceutical by 85 million yuan
Zhongmu Shares (Announced, the resolution of the third extraordinary meeting of the eighth board of directors of the company in 2021) to consider and pass the proposal on the capital increase of Zhongmu Nanjing Animal Pharmaceutical Co., Ltd. Agreed that the company would increase the capital of its wholly-owned subsidiary, Zhongmu Nanjing Animal Pharmaceutical Co., Ltd., by 85 million yuan.
15. Qilu Pharmaceutical's 3 billion green biological agricultural and veterinary drug project has been steadily promoted
The reporter learned that the Qilu Pharmaceutical Project, which invested 3 billion yuan to build a green biological agricultural and veterinary drug industry poverty alleviation project, is steadily advancing, and 3 product production lines have been put into operation. The project mainly builds high-end biological agricultural and veterinary drug production lines such as polycycline, at present, 3 product production lines have been put into operation, and the fourth product extraction workshop has completed the construction of the plant, equipment installation is underway, and it is expected to be put into use at the end of October.
16. The veterinary drug base project of 430 million yuan settled in Shenyang
On September 9, 2021, Shenyang Weijia Biotechnology Co., Ltd. settled in Shenyang with an annual output value of 700 million yuan. The total investment of the project is 430 million yuan, a total of 9 production lines and 11 dosage forms. After the completion of the project, it will be the largest research, production and marketing of new biological veterinary drug manufacturing and operation bases in the three northeastern provinces, and the largest research and development center for high-tech value-added biological veterinary drug innovative preparations in the northern region.
17. The second phase of the Inner Mongolia Jiupeng Phase II project of 1 billion yuan was started
On September 11, the groundbreaking ceremony of the second phase project of Inner Mongolia Jiupeng Pharmaceutical Co., Ltd., which invested 1 billion yuan, namely 2,000 tons of doxycycline hydrochloride and 1,500 tons of oxytetracycline hydrochloride, was held in Kailu Biomedical Development Zone.
18. Yongan Pharmaceutical plans to build another 40,000 tons of taurine
Yongan Pharmaceutical announced that the company intends to use its own funds of 250 million yuan to expand the annual output of 40,000 tons of taurine food additive project.
19. The R&D and production base of intelligent green Chinese veterinary drug preparations is expected to be officially put into operation at the end of January next year
Sichuan Hengtong Dongbao Biotechnology Co., Ltd. Phase II project - intelligent green Chinese veterinary drug preparation R & D and production base project since the start of construction in December last year, the progress is smooth, the current infrastructure has been completed, is expected to be trial production in January 2022, officially put into operation at the end of January 2022.
20. North China Pharmaceutical Kailu County Base Project held a testing ceremony
On October 20th, the commissioning ceremony of the "Inner Mongolia Kailu Biological Fermentation Base" project of North China Pharmaceutical was held. The completion and commissioning of the Kailu project marks the construction and improvement of the "five major industrial bases" of Chinese medicine.